UT Health San Antonio Gains $2M to Study Rapamycin for Alzheimer's
August 26, 2020
August 26, 2020
SAN ANTONIO, Texas, Aug. 26 -- The University of Texas Health Science Center at San Antonio issued the following news release:
In the war on cancer and other diseases including COVID-19, old drugs approved for other conditions are being studied for new purposes. It's a strategy that will now be tested in Alzheimer's disease with a drug called rapamycin.
A $2 million grant will enable a double-blind, placebo-controlled clinical trial in which 40 individuals wit . . .
In the war on cancer and other diseases including COVID-19, old drugs approved for other conditions are being studied for new purposes. It's a strategy that will now be tested in Alzheimer's disease with a drug called rapamycin.
A $2 million grant will enable a double-blind, placebo-controlled clinical trial in which 40 individuals wit . . .